紫杉醇致卵巢癌患者严重心律失常1例

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Paclitaxel is an antitumor drug with unique structure and mechanism of action.Paclitaxel combined with Platinum is the first-choice chemotherapy for ovarian cancer treatment.Cardiotoxicity of Paclitaxel is rare,but there are reports that the drug can cause a series of cardiac changes such as asymptomatic eletrocardiogram abnormalities,blood pressure changes,arrhythmias,myocarditis,pericarditis,tamponade,acute myocardial infarction,heart failure,shock,chronic cardiomyopathy,etc,which reduce heart function of patients,thus affecting curative effect,reducing the quality of life,and these changes may occur during medication or several years after medication.Therefore,it is of great significance in tumor therapy to discover the cardiotoxicity of Paclitaxel as early as possible and take effective measures to reduce the occurrence of cardiac complications.The mechanism and treatment scheme of Paclitaxel-induced arrhythmia were analyzed and discussed through a case of arrhythmia in ovarian cancer patient after Paclitaxel administration.

Key words： Paclitaxel Arrhythmia Cisplatin Chemotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xiu-xiu
	YANG Bing

Cite this article:

WANG Xiu-xiu,YANG Bing. One case of severe arrhythmia caused by Paclitaxel in ovarian cancer patient[J]. 中国当代医药, 2020, 27(21): 189-194.

URL:

https://dangdaiyiyao.com/EN/ OR https://dangdaiyiyao.com/EN/Y2020/V27/I21/189

[1]	Kaldawy A，Segev Y，Lavie O，et al.Low-grade serous ovarian cancer：A review[J].Gynecol Oncol，2016，143（2）：433-438.
[3]	Siegel RL，Miller KD，Jemal A.Cancer Statistics，2019[J].CA Cancer J Clin，2019，69（1）：7-34.
[4]	李翔，鲁艳明，张瑶.紫杉醇联合顺铂新辅助化疗在早中期宫颈癌治疗中的临床应用[J].实用药物与临床，2016，19（2）：148-151.
[5]	李小平，姜杰，尹如铁，等.妇科恶性肿瘤紫杉醇类药物临床应用专家共识[J].现代妇产科进展，2019，28（10）：724-730.
[2]	Poole EM，Konstantinopoulos PA，Terry KL.Prognostic implications of reproductive and lifestyle factors in ovarian cancer[J].Gynecol Oncol，2016，142（3）：574-587.
[6]	马力，时俊锋，童宁.紫杉醇类药物的不良反应研究[J].中国药房，2018，29（21）：3014-3017.
[7]	周艳.抗肿瘤药紫杉醇的不良反应及临床合理用药分析[J].中国现代药物应用，2017，11（9）：138-139.
[8]	CastelM，DespasF，ModestoA，etal.Cardiotoxicityofchemotherapies[J].Presse Med，2013，42（1）：26-39.
[9]	Bergler-Klein J.Strain and left ventricular volumes for predicting cardiotoxicity：a life-saving approach in anthracycline cancer treatment?[J].Eur Heart J Cardiovasc Imaging，2015，16（9）：968-969.
[10]	Schimmel KJ，Richel DJ，van den Brink RB，et al.Cardiotoxicity of cytotoxic drugs[J].Cancer Treat Rev，2004，30（2）：181-191.
[11]	杨兴艳，薛月珍.紫杉醇心脏毒性研究进展[J].医药导报，2009，28（8）：1064-1067.
[12]	NCCN guideline of Epithelial Ovarian Cancer （including Fallopian Tube Cancer and Primary Peritoneal Cancer），2019 V1.https：//www.nccn.org.
[13]	徐艳萍，纳丽莎，贾梅，等.常规超声心动图对乳腺癌患者蒽环类药物化疗后心脏毒性的监测[J].宁夏医科大学学报，2016，38（4）：456-458.
[14]	Untch M，Jackisch C，Schneeweiss A，et al.Nab-paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer（GeparSepto-GBG 69）：A Randomised，Phase 3 Trial[J].Lancet Oncol，2016，17（3）：345-356.
[15]	肖仁斌，彭辉，王江涛，等.紫杉醇脂质体治疗晚期食管癌的效果[J].中国当代医药，2019，26（29）：72-74.
[16]	陈建英，刘瑾，张俊辉，等.紫衫醇脂质体对卵巢癌细胞增殖及转移能力的影响及其相关机制[J].中国临床药理学杂志，2018，34（23）：2715-2718.
[17]	唐慕菲，朱余兵，李杨，等.紫杉醇脂质体与紫杉醇分别联合卡铂治疗卵巢癌疗效的Meta 分析[J].中国药师，2018，21（4）：657-661.
[18]	詹德超，陈梓宏，温继育，等.多西紫杉醇在局部晚期鼻咽癌奈达铂同期放化疗中联合使用的临床效果观察[J].中国医药科学，2018，8（6）：198-200.
[19]	Maschmeyer G，Helweg-Larsen J，Pagano L，et al.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients[J].J Antimicro Chemother，2016，71（9）：2405-2413.